GoodRx (NASDAQ:GDRX) PT Lowered to $10.00 at Deutsche Bank Aktiengesellschaft

GoodRx (NASDAQ:GDRXGet Rating) had its price objective reduced by research analysts at Deutsche Bank Aktiengesellschaft from $20.00 to $10.00 in a research note issued to investors on Wednesday, The Fly reports. Deutsche Bank Aktiengesellschaft’s price target indicates a potential upside of 25.47% from the stock’s current price.

Other research analysts have also recently issued reports about the company. JPMorgan Chase & Co. decreased their price target on GoodRx from $33.00 to $20.00 and set an “underweight” rating on the stock in a research note on Tuesday, March 1st. Credit Suisse Group dropped their price objective on shares of GoodRx from $22.00 to $10.00 in a report on Wednesday. Cowen lowered shares of GoodRx from an “outperform” rating to a “market perform” rating and reduced their target price for the stock from $49.00 to $22.00 in a report on Tuesday, March 1st. SVB Leerink downgraded shares of GoodRx from an “outperform” rating to a “market perform” rating and dropped their price target for the stock from $33.00 to $10.00 in a research note on Tuesday. Finally, Raymond James cut GoodRx from an “outperform” rating to a “market perform” rating in a research note on Tuesday. One research analyst has rated the stock with a sell rating, ten have issued a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $25.50.

Shares of GDRX opened at $7.97 on Wednesday. The company’s 50-day moving average price is $16.47 and its 200 day moving average price is $27.30. GoodRx has a 12-month low of $7.33 and a 12-month high of $48.05. The company has a current ratio of 13.42, a quick ratio of 13.42 and a debt-to-equity ratio of 0.79. The firm has a market cap of $3.19 billion, a P/E ratio of -113.84, a price-to-earnings-growth ratio of 4.42 and a beta of 0.29.

GoodRx (NASDAQ:GDRXGet Rating) last released its quarterly earnings results on Monday, May 9th. The company reported $0.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.02 by $0.01. GoodRx had a negative net margin of 3.39% and a positive return on equity of 0.06%. The business had revenue of $203.30 million for the quarter, compared to the consensus estimate of $200.61 million. During the same period in the previous year, the firm earned ($0.01) EPS. The business’s revenue was up 26.7% on a year-over-year basis. Equities research analysts forecast that GoodRx will post 0.17 earnings per share for the current year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in GDRX. IFP Advisors Inc increased its position in shares of GoodRx by 301.0% during the fourth quarter. IFP Advisors Inc now owns 1,163 shares of the company’s stock worth $41,000 after purchasing an additional 873 shares in the last quarter. First Horizon Advisors Inc. increased its position in GoodRx by 208.2% during the third quarter. First Horizon Advisors Inc. now owns 1,350 shares of the company’s stock worth $42,000 after buying an additional 912 shares during the period. CWM LLC purchased a new stake in GoodRx in the fourth quarter valued at approximately $48,000. Spire Wealth Management boosted its holdings in shares of GoodRx by 50.0% in the fourth quarter. Spire Wealth Management now owns 1,500 shares of the company’s stock valued at $49,000 after acquiring an additional 500 shares during the period. Finally, AdvisorNet Financial Inc grew its position in shares of GoodRx by 275.0% during the first quarter. AdvisorNet Financial Inc now owns 1,875 shares of the company’s stock worth $36,000 after acquiring an additional 1,375 shares during the last quarter. Institutional investors own 52.60% of the company’s stock.

GoodRx Company Profile (Get Rating)

GoodRx Holdings, Inc, through its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States.

Featured Articles

The Fly logo

Analyst Recommendations for GoodRx (NASDAQ:GDRX)

Receive News & Ratings for GoodRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GoodRx and related companies with MarketBeat.com's FREE daily email newsletter.